News

How mazdutide compares against weight loss therapies from Novo Nordisk, Lilly
How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Investor's Business Daily on MSN15h
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.